10-K – 2025-12-05 – coo-20251031.htm

(In millions) United
States Europe Rest of
World, Other
Eliminations
& Corporate Consolidated
2025
Net sales to unaffiliated customers $ 2,054.0   $ 1,253.2   $ 785.2   $ 4,092.4  
Sales between geographic areas 679.0   1,124.8   ( 1,803.8 ) — 
Net sales $ 2,733.0   $ 2,378.0   $ ( 1,018.6 ) $ 4,092.4  
Operating income $ 4.2   $ 662.1   $ 16.6   $ 682.9  
Long-lived assets $ 1,389.4   $ 429.1   $ 263.5   $ 2,082.0  
2024
Net sales to unaffiliated customers $ 1,965.9   $ 1,155.9   $ 773.6   $ 3,895.4  
Sales between geographic areas 602.9   1,065.2   ( 1,668.1 ) — 
Net sales $ 2,568.8   $ 2,221.1   $ ( 894.5 ) $ 3,895.4  
Operating income $ 74.2   $ 601.8   $ 29.7   $ 705.7  
Long-lived assets $ 1,188.8   $ 401.7   $ 272.9   $ 1,863.4  
2023
Net sales to unaffiliated customers $ 1,812.2   $ 1,041.2   $ 739.8   $ 3,593.2  
Sales between geographic areas 563.1   1,016.7   ( 1,579.8 ) — 
Net sales $ 2,375.3   $ 2,057.9   $ ( 840.0 ) $ 3,593.2  
Operating (loss) income $ —   $ 516.2   $ 16.9   $ 533.1  
Long-lived assets $ 1,027.6   $ 325.9   $ 279.1   $ 1,632.6  

87

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Note 13. Financial Derivatives and Hedging
As part of the Company’s overall risk management practices the Company enters into financial derivatives, interest rate swaps designated as cash flow hedges, to hedge the Company's exposure to changes in cash flows associated with its variable rate debt.
Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk. From time to time, the Company enters into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain trade and intercompany receivables and payables. These foreign currency forward contracts are not designated as hedging instruments, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Income and Comprehensive Income. As of October 31, 2025, the notional amount of outstanding foreign currency forward contracts was $ 54.5  million. The resulting impact on our Consolidated Financial Statements from currency hedging activities was not significant for the years ended October 31, 2025, 2024 and 2023.
As of October 31, 2025, the Company has eight interest rate swap contracts that have a total notional amount of $ 1.6  billion and remaining maturities of less than three years .
The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:

Periods Ended October 31,
(In millions) 2025 2024 2023
Derivatives designated as cash flow hedges Location of (Gain)/Loss Recognized on Derivatives
Interest rate swap contracts Interest expense (income) $ ( 36.1 ) $ ( 55.0 ) $ ( 43.1 )

The cumulative pre-tax impact of the gain on derivatives designated for hedge accounting is recognized in "Accumulated other comprehensive loss". The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:

(In millions) Amount
Balance gain as of October 31, 2023
$ 115.1  
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($( 0.6 ), net of tax)
( 0.9 )
Amount reclassified from other comprehensive income into earnings, gross ($( 41.9 ), net of tax)
( 55.0 )
Balance gain as of October 31, 2024
$ 59.2  
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($ 0.5 , net of tax)
0.6  
Amount reclassified from other comprehensive income into earnings, gross ($( 27.4 ), net of tax)
( 36.1 )
Balance gain as of October 31, 2025
$ 23.7  

Refer to Note 8. Stockholders’ Equity for amounts presented net of the related tax impact in "Accumulated other comprehensive loss".
The Company expects that $( 20.2 ) million recorded as a component of "Accumulated other comprehensive loss" will be realized in the Consolidated Statements of Income over the next twelve months and the amount will vary depending on prevailing interest rates.
88

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.

Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
The Company has established and currently maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
In conjunction with the close of each fiscal quarter, the Company conducts a review and evaluation, with participation of the Company's management, and under the oversight of the Board of Directors, including the Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer), of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's Chief Executive Officer and Chief Financial Officer based upon their evaluation as of October 31, 2025, the end of the fiscal period covered in this report, concluded that the Company's disclosure controls and procedures were effective at the reasonable assurance level.
Management's Annual Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements, errors or fraud.
Management assessed the effectiveness of the Company's internal control over financial reporting as of October 31, 2025, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013) . Based on this assessment, management, with participation of the Company's Chief Executive Officer and Chief Financial Officer, and under the oversight of the Board of Directors, concluded that the Company's internal control over financial reporting was effective as of October 31, 2025.
As disclosed in Part II - Item 9A of the Company's Annual Report on Form 10-K for the year ended October 31, 2024, management identified material weaknesses in internal control over financial reporting related to information technology (IT) general controls for the U.S. operations within the CooperSurgical segment, associated with the implementation and maintenance of certain enterprise resource planning systems (ERP) during fiscal year 2024. The material weakness resulted from not having a sufficient complement of its personnel, inadequate training of personnel and ineffective risk assessment processes to identify and timely respond to the risks related to change management, user control monitoring and segregation of duties in the affected IT environment. Manual controls that rely on system-generated data or reports from the affected IT environment or process level automated controls in the affected IT environment were ineffective because they could have been adversely impacted.
During fiscal year 2025, management, with oversight of the Audit Committee of the Board of Directors, implemented steps to remediate the material weakness. Our internal control remediation efforts included the following:
• Enhancing risk assessment and procedures over our IT general controls for the affected environments;
• Developing the skill sets of employees and additional training programs addressing IT general controls and policies with a focus on those related to change management, user access and segregation of duties over IT systems impacting financial reporting;
• Enhancing controls supporting change management to ensure systems’ integrity as well as user access monitoring controls to enforce appropriate system access and segregation of duties.
During the quarter ended October 31, 2025, we completed our testing of the design and operating effectiveness of the implemented controls and found them to be effective. As a result, we have concluded the material weakness has been remediated as of October 31, 2025.
89

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

The Company's independent registered public accounting firm, KPMG LLP, has audited the effectiveness of the Company's internal control over financial reporting as of October 31, 2025, as stated in their report in Part II, Item 8 of this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
Except as set forth above, there have been no changes in our internal control over financial reporting during the quarter ended October 31, 2025, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Item 9B. Other Information.
During the three months ended October 31, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
90

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

PART III

Item 10. Directors, Executive Officers and Corporate Governance.
The information required by this item is incorporated by reference to the Company’s Proxy Statement for the 2026 Annual Meeting of Stockholders (the 2026 Proxy Statement).

Item 11. Executive Compensation.
The information required by this item is incorporated by reference to the 2026 Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
See Item 5. Market for Registrant's Common Equity and Related Stockholder Matters - Equity Compensation Plan Information. Additional information required by this item is incorporated by reference to the 2026 Proxy Statement.

Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item is incorporated by reference to the 2026 Proxy Statement.

Item 14. Principal Accounting Fees and Services.
The information required by this item is incorporated by reference to the 2026 Proxy Statement.

91

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

PART IV

Item 15. Exhibits and Financial Statement Schedules.
(a)    Financial Statements
The following financial statements are filed as a part of this report:
Report of KPMG LLP, Independent Registered Public Accounting Firm
Consolidated Financial Statements:
Statements of Income for the years ended October 31, 2025, 2024 and 2023
Statements of Comprehensive Income for the years ended October 31, 2025, 2024 and 2023
Balance Sheets as of October 31, 2025, and 2024
Statements of Stockholders' Equity for the years ended October 31, 2025, 2024 and 2023
Statements of Cash Flows for the years ended October 31, 2025, 2024 and 2023
Notes to Consolidated Financial Statements.
(b)     Exhibits.
The exhibits listed on the accompanying Exhibit Index are filed as part of this report.
All other schedules which are included in the applicable accounting regulations of the Securities and Exchange Commission are not required here because they are not applicable.

92

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

EXHIBIT INDEX

Incorporated by Reference
Exhibit Number Description of Document
Form Exhibit Filing Date/
Period End
Date
3.1 Second Restated Certificate of Incorporation
8-K 3.1 1/13/2006
3.2 Amendment to Second Restated Certificate of Incorporation
10-Q 3.1 3/1/2024

3.3 Amended and Restated By-Laws, The Cooper Companies, Inc, dated October 22, 2024
8-K
3.1
10/25/2024

3.4 Amendment to Second Restated Certificate of Incorporation
10-Q 3.1 5/30/2025

4.1 Description of Securities of The Cooper Companies, Inc. Registered under Section 12 of the Exchange Act
8-A 9/25/2023
10.1# The Cooper Companies, Inc. Change in Control Severance Plan, dated May 21, 2007
10-Q 10.1 7/31/2007
10.2# Executive Employment Agreement by and between The Cooper Companies, Inc. and Albert G. White III, effective as of March 19, 2024
10-Q 10.2
4/30/2024

10.3# Executive Employment Agreement by and between The Cooper Companies, Inc. and Daniel G. McBride, effective as of March 19, 2024
10-Q 10.3 4/30/2024
10.4# Executive Employment Agreement by and between The Cooper Companies, Inc. and Brian G. Andrews, effective as of November 1, 2018
10-Q 10.2 4/30/2019
10.5#
Executive Employment Agreement by and between The Cooper Companies, Inc. and Holly R. Sheffield, effective as of November 1, 2018
10-Q 10.4 4/30/2019
10.6# The Third Amended and Restated 2007 Long-Term Incentive Plan of The Cooper Companies, Inc.
14A A 1/29/2016
10.7# Form of Non-Qualified Stock Option Agreement Pursuant to the 2007 Long-Term Incentive Plan of The Cooper Companies, Inc.
10-K 10.32 10/31/2007
10.8# Form of Deferred Stock Agreement Pursuant to the 2007 Long-Term Incentive Plan of The Cooper Companies, Inc.
10-K 10.34 10/31/2007
10.9# Form of Long Term Performance Share Award Agreement Pursuant to the 2007 Long-Term Incentive Plan of The Cooper Companies, Inc.
8-K 10.1 2/13/2009
10.10# The Cooper Companies, Inc.’s 2019 Employee Stock Purchase Plan
14A A 2/1/2019
10.11# The 2020 Long Term Incentive Plan for Non-Employee Directors of The Cooper Companies, Inc.
14A A 2/4/2020
10.12# Form of Restricted Stock Unit Agreement pursuant to the 2020 Long Term Incentive Plan for Non-Employee Directors of The Cooper Companies, Inc.
10-K
10.12 10/31/2024
10.13 (a)
License Agreement dated as of November 19, 2007, by and among CIBA Vision AG, CIBA Vision Corporate and CooperVision, Inc.
10-K 10.41 10/31/2008
10.14 (a)
Amendment No. 1 to the License Agreement dated as of November 19, 2007, by and among CIBA Vision AG, CIBA Vision Corporate and CooperVision, Inc.
8-K 99.1 12/21/2012
10.15 Lease Contract dated as of November 6, 2003, by and between The Puerto Rico Industrial Development Company and Ocular Sciences Puerto Rico, Inc.
8-K 10.1 1/12/2005
10.16 First Supplement and Amendment to Lease Contract dated as of December 30, 2003, by and between The Puerto Rico Industrial Development Company and Ocular Sciences Puerto Rico, Inc.
8-K 10.2 1/12/2005
10.17 Assignment of Lease Agreement dated as of June 29, 2004, by and among Ocular Sciences Puerto Rico, Inc., Ocular Sciences Cayman Islands Corporation and The Puerto Rico Industrial Development Company
8-K 10.3 1/12/2005
10.18 Revolving Credit and Term Loan Agreement, dated as of April 1, 2020, among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft., the lenders from time to time party thereto and KeyBank National Association, as administrative agent
8-K 10.1 4/2/2020
10.19 Amendment No. 1 and Joinder, dated as of October 30, 2020, to Revolving Credit and Term Loan Agreement, dated as of April 1, 2020, among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft., the lenders from time to time party thereto and KeyBank National Association, as administrative agent
10-K 10.20 10/31/2020

93

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Incorporated by Reference
Exhibit Number Description of Document
Form Exhibit Filing Date/
Period End
Date
10.20 Term Loan Agreement, dated as of December 17, 2021, by and among The Cooper Companies, Inc., the lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent.
8-K 10.1 12/17/2021
10.21 Amendment No.2 and Joinder, dated as of December 17, 2021, to Revolving Credit and Term Loan Agreement, dated as of April 1, 2020, among the Company, CooperVision International Limited, CooperVision Holding Kft., CooperSurgical Holdings Limited, the lenders party thereto, and KeyBank, National Association, as administrative agent
10-Q 10.3 1/31/2022

10.22 Amendment No.1, dated as of February 1, 2023, to the Term Loan Agreement, dated as of December 17, 2021, by and among The Cooper Companies, Inc. and PNC Bank, National Association, as the administrative agent.
10-Q 10.1 1/31/2023
10.23 Amendment No. 3, dated as of February 1, 2023, to the Revolving Credit and Term Loan Agreement, dated as of April 1, 2020, by and among the Company, CooperVision International Limited, and CooperSurgical Holdings Limited, the borrowers party thereto, and KeyBank National Association, as administrative agent.
10-Q 10.2 1/31/2023
10.24#
The Cooper Companies, Inc. 2023 Long-Term Incentive Plan
14A A 1/30/2023
10.25#
Form of Stock Option Agreement for the 2023 Long-Term Incentive Plan
10-Q 10.2 4/30/2023
10.26#
Form of Restricted Stock Unit Agreement for the 2023 Long-Term Incentive Plan
10-Q 10.3 4/30/2023
10.27#
Form of Performance Stock Unit Agreement for the 2023 Long-Term Incentive Plan
10-Q 10.4 4/30/2023
10.28#
The Cooper Companies, Inc. 2017 Executive Incentive Plan
14A A 1/27/2017
10.29#
The Cooper Companies, Inc. Compensation Recovery Policy
10-K
10.32
10/31/2023
10.30#
Executive Employment Agreement by and between The Cooper Companies, Inc. and Gerard Warner, effective as of March 19, 2024
10-Q 10.1
4/30/2024
10.31 Revolving Credit Agreement, dated as of May 1, 2024, among the Company, CooperVision International Limited, the lenders from time to time party thereto and PNC Bank National Association, as administrative agent
8-K
10.1
5/1/2024

10.32 Amendment No. 2, dated as of May 1, 2024, to the Term Loan Agreement, dated as of December 17, 2021, by and among The Cooper Companies, Inc., the lenders party thereto, and PNC Bank, National Association, as the administrative agent .
8-K
10.2
5/1/2024

19.1 Insider Trading Compliance Policy

21 Subsidiaries

23 Consent of Independent Registered Public Accounting Firm

31.1 Certification of the Chief Executive Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2 Certification of the Chief Financial Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1* Certification of the Chief Executive Officer, pursuant to 18 U.S.C. Section 1350

32.2* Certification of the Chief Financial Officer, pursuant to 18 U.S.C. Section 1350

101 The following materials from the Company's Annual Report on Form 10-K for the year ended October 31, 2024, formatted in Inline XBRL (Extensible Business Reporting Language):(i) Consolidated Statements of Income for the years ended October 31, 2024, 2023 and 2022 (ii) Consolidated Statements of Comprehensive Income for the years ended October 31, 2024, 2023 and 2022 (iii) Consolidated Balance Sheets at October 31, 2024 and 2023, (iv) Consolidated Statements of Stockholders' Equity for the years ended October 31, 2024, 2023 and 2022 (v) Consolidated Statements of Cash Flows for the years ended October 31, 2024, 2023 and 2022, (vi) related notes to consolidated financial statements
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

(a)    The agreement received confidential treatment from the Securities and Exchange Commission with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Commission.
#    Indicates management contract or compensatory plan.
94

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of The Cooper Companies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.
95

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Item 16. Form 10-K Summary .
None.

96

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on December 5, 2025.
THE COOPER COMPANIES, INC.
By: /s/ Albert G. White, III
Albert G. White, III
President & Chief Executive Officer

POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Albert G. White, III, Brian G. Andrews, and Daniel G. McBride, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on the dates set forth opposite their respective names.

Signature Capacity Date
/s/ ALBERT G. WHITE, III President, Chief Executive Officer and Director (Principal Executive Officer) December 5, 2025
(Albert G. White, III)
/s/ ROBERT S. WEISS Chairman of the Board December 5, 2025
(Robert S. Weiss)
/s/ BRIAN G. ANDREWS Executive Vice President, Chief Financial Officer and Treasurer December 5, 2025
(Brian G. Andrews) (Principal Financial Officer)
/s/ AGOSTINO RICUPATI Senior Vice President and Chief Accounting Officer December 5, 2025
(Agostino Ricupati) (Principal Accounting Officer)
/s/ BARBARA CARBONE
Director December 5, 2025
(Barbara Carbone)

/s/ COLLEEN E. JAY Director December 5, 2025
(Colleen E. Jay)
/s/ CYNTHIA L. LUCCHESE
Director December 5, 2025
(Cynthia L. Lucchese)
/s/ LAWRENCE KURZIUS
Director December 5, 2025
(Lawrence Kurzius)
/s/ MARIA RIVAS M.D. Director December 5, 2025
(Maria Rivas M.D.)
/s/ TERESA S. MADDEN Director December 5, 2025
(Teresa S. Madden)

97

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

CORPORATE INFORMATION

BOARD OF DIRECTORS

Weiss, Robert S.
Chairman of the Board

Carbone, Barbara
Director

Jay, Colleen E.
Director

Kurzius, Lawrence
Director

Lucchese, Cynthia L.
Director

Madden, Teresa S.
Director

Rivas, Maria, M.D.
Global Chief Medical Officer for Specialty and Primary Care and Head, Evidence Generation, Pfizer, Inc.

White, Albert G., III
President & Chief Executive Officer

COMMITTEES OF THE BOARD

Audit Committee
Madden, Teresa S. (Chairman)
Carbone, Barbara
Rivas, Maria, M.D.

Corporate Governance and Nominating Committee
Lucchese, Cynthia L. (Chairman)
Kurzius, Lawrence
Rivas, Maria, M.D.

 
Organization and Compensation Committee
Jay, Colleen E. (Chairman)
Kurzius, Lawrence
Lucchese, Cynthia L
EXECUTIVE OFFICERS

White, Albert G., III
President and Chief Executive Officer

McBride, Daniel G.
Executive Vice President, Chief Operating Officer, General Counsel and Corporate Secretary

Andrews, Brian G.
Executive Vice President, Chief Financial Officer and Treasurer

Ricupati, Agostino
Senior Vice President and Chief Accounting Officer

Sheffield, Holly R.
President of CooperSurgical, Inc.

Warner, Gerard H., III
President of CooperVision, Inc.

PRINCIPAL SUBSIDIARIES

CooperVision, Inc.
6101 Bollinger Canyon Road
Suite 500
San Ramon, CA 94583
925-460-3600
www.coopervision.com

CooperSurgical, Inc.
75 Corporate Drive
Trumbull, CT 06611
203-601-5200
www.coopersurgical.com

CORPORATE OFFICES

The Cooper Companies, Inc.
6101 Bollinger Canyon Road
Suite 500
San Ramon, CA 94583
925-460-3600
www.coopercos.com

INVESTOR INFORMATION

Recent news releases, the annual report on Securities and Exchange Commission Form 10-K, information about the Company's corporate governance program, recent investor presentations, replays of quarterly conference calls and historical stock quotes are available on our website at www.coopercos.com.

INVESTOR RELATIONS CONTACT

Kim Duncan
Vice President, Investor Relations and Risk Management
6101 Bollinger Canyon Road
Suite 500
San Ramon, CA 94583
Voice: 925-460-3663
E-mail: ir@cooperco.com

ANNUAL MEETING

The Cooper Companies will hold its Annual Stockholders' Meeting in April 2026.

TRANSFER AGENT

Equiniti Trust LLC
48 Wall Street, Floor 23
New York, NY 10005
800-937-5449

TRADEMARKS

CooperVision, CooperSurgical, and other trade names, trademarks or service marks of CooperCompanies and its subsidiaries appearing in this report are the property of CooperCompanies and its subsidiaries. Trade names, trademarks and service marks of the other companies appearing in this report are the property of their respective holders.

INDEPENDENT AUDITORS

KPMG LLP

STOCK EXCHANGE LISTING

Nasdaq Global Select Market
Ticker Symbol “COO”

98